If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
210
results.
Updated on
21/02/2026 [06:51:00]
Results 125 to 150 of 210
Absstract of: WO2026036007A1
The present invention provides a pharmaceutical-acceptable lipid nanoparticle (LNP) composition for delivering active agents to the bone marrow. The LNP comprises a ganglioside, a cholesterol, a phospholipid, and a cationic or ionizable lipid and exhibits superior transfection efficiency in bone marrow cells relative to other lipid nanoparticles that lack the ganglioside.
Absstract of: WO2026035909A1
This disclosure relates to split-formulated influenza vaccines and methods of immunizing a subject against influenza using the same.
Absstract of: WO2026034613A1
The present invention provides an adjuvant comprising a B-type CpG oligodeoxynucleotide (CpG ODN), a modification thereof, or a complex thereof, to be administered together with an mRNA vaccine in which mRNA is encapsulated in particles. The adjuvant contains the B-type CpG ODN that is present independently of the particles that encapsulate mRNA. This adjuvant can enhance antigen-specific cytotoxic T cell (CTL) induction by mRNA vaccines.
Absstract of: WO2026033240A1
The invention relates to compounds of general formula (I), where X1, X2, X3 and y are defined in the description. The invention further relates to a process for the preparation of said compounds, and to the use of said compounds for the preparation of lipid nanoparticles carrying active ingredients. The invention further relates to a pharmaceutical composition comprising a nanoparticle according to the invention, and to the nanoparticle for use in medicine.
Absstract of: WO2026031838A1
The present invention belongs to the field of pharmaceutical formulations. Specifically disclosed are a nanodrug for synergistically removing fibrosis and inhibiting pancreatic cancer metastasis and a preparation method therefor. By means of the self-assembly of a small-molecule prodrug, excipient-related toxicity is avoided, and a high drug loading rate is achieved. By means of hybrid membrane encapsulation, homologous targeting of fibrotic adhesion interstitium and receptor protein-mediated active targeting are achieved. By means of the response of the prodrug molecule to ROS, massive, rapid, and traceless drug release is achieved in the fibrotic adhesion interstitium, removing the self-limiting characteristic of the release of a responsive small-molecule drug. The released drugs Cap and CA can simultaneously inhibit fibrosis signals/proteins, synergistically removing fibrosis. As the removal of fibrosis progresses, Cap and CA released rapidly and tracelessly in pancreatic cancer cells can simultaneously inhibit the metastasis/invasion signaling pathway of pancreatic cancer cells, synergistically inhibiting metastasis. The dynamic synergy between the process of removing fibrosis and the process of inhibiting metastasis provides a new approach for removing fibrosis in the treatment of pancreatic cancer.
Absstract of: WO2026030816A1
Provided is a lipid nanoparticle comprising capped mRNA bearing one or more ribose modifications, and 20 to 70 mol % of a neutral lipid, an ionizable lipid; and a sterol and optionally a hydrophilic polymer-lipid conjugate, the lipid nanoparticles exhibiting at least a 10% increase in extrahepatic protein expression of the mRNA in vivo, as measured in one or more extrahepatic organs or tissues. In some examples, the mRNA comprises a 5' cap having an N7-methylated guanosine at a position 0, and a nucleoside at a position 1 linked to the N7-methylated guanosine by a 5' to 5' bridge, wherein the N7-methylated guanosine has a modification at a 3' carbon of its ribose and/or the nucleoside at the position 1 has a modification at a 2' carbon of its ribose.
Absstract of: AU2024322403A1
The present application provides compositions, methods, and dispensers for topical delivery of ophthalmological active pharmaceutical ingredients (APIs). In one example, a composition is provided comprising an active pharmaceutical ingredient soluble in MCT wherein the API is not atropine or a salt thereof; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound. In another example, a nano-emulsion is provided comprising about an active pharmaceutical ingredient soluble in MCT; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound, wherein the nano-emulsion has a droplet particle size D90 of less than about 100 nm. Dispensers containing the compositions are also provided and include glass and polyethylene terephthalate dispensers or containers. Methods of using the compositions are also provided and include a method for treating an ocular condition in a subject comprising administering the compositions or nano-emulsions to an eye of the subject. The present application also provides compositions and methods for treating ophthalmological conditions such as presbyopia and glaucoma. The compositions can comprise a muscarinic cholinergic receptor agonist and a semi-fluorinated alkane compound; or can comprise a muscarinic cholinergic receptor agonist, a semi-fluorinated alkane compound, and an organic cosolvent. The compositions can confer chemical stability of the muscarinic cholinergic receptor agonist.
Absstract of: AU2024310306A1
The present invention provides, in part, dianhydrohexitol-based cationic lipids of Formula (I), and sub-formulas thereof: (I), or a pharmaceutically acceptable salt thereof. The present invention also provides, in part, dianhydrohexitol-based cationic lipids of Formula (II), and sub-formulas thereof: (II), or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.
Absstract of: AU2024308529A1
Provided are lipid nanoparticles for delivering nucleic acids molecules such as mRNA. Also provided are methods of making and using thereof.
Absstract of: AU2025270991A1
The present disclosure relates to methods and compositions comprising derivatized-chitosan polyplexes reversibly coated with a polyanion-containing block co-polymer for the localized expression of IL-12 in mucosal tissues, preferably in combination with an IFN- 1 activator/inducer, for use in cancer immunotherapy. ov o v
Absstract of: AU2024316257A1
Excipient granulations containing a viscosifying agent, a disintegrant, and one or more additional excipients are disclosed. An excipient granulation can be combined with a pharmaceutical granulation to provide a pharmaceutical composition. The excipient granulations can be used to increase the viscosity of an aqueous composition such as an oral pharmaceutical composition. When added to an aqueous solution, the excipient granulation can dissolve to provide a suspension of the pharmaceutical granules in a viscous solution. The excipient granulation can be used to improve the palatability of oral pharmaceutical compositions containing a pharmaceutical granulation.
Absstract of: US20260042732A1
Lipid nanoparticle compositions (LNPs), methods for preparing the LNPs, methods of using the same, including, but not limited to, for treatment of certain diseases and disorders, including, but not limited to liver disorders, kits for the delivery of nucleic acids to various types of cells, including T-cells and hepatocytes, in vivo, ex vivo and in vitro.
Absstract of: EP4691500A2
An object of the present invention is to provide a lipid composition capable of realizing an excellent nucleic acid delivery efficiency. According to the present invention, there is provided a lipid composition containing a compound represented by Formula (1), a lipid represented by Formula (2) or a salt of the lipid, a neutral lipid, a nonionic hydrophilic polymer, and a lipid having a nucleic acid.The definition of each symbol in the formulae is as described in the present specification.
Absstract of: EP4691478A1
The present invention relates to a pharmaceutical composition for treating cartilage damage disease, the pharmaceutical composition comprising magnetic nanoparticle-internalized nasal septum chondrocytes as an active ingredient. In addition, the present invention established a method of incorporating magnetic nanoparticles into nasal septum chondrocytes and a method of producing spheroids by culturing the magnetic nanoparticle-internalized nasal septum chondrocytes. The magnetic nanoparticle-internalized nasal septum chondrocytes manufactured by the methods of the present invention, and spheroids produced therefrom were confirmed to exhibit cartilage damage treatment activity while maintaining mobility in a magnetic field. In addition, since the activity is maintained even when the magnetic nanoparticle-internalizednasal septum chondrocytes and nasal septum chondrocytes are mixed to produce spheroids, the addition ratio of the magnetic nanoparticles can be significantly reduced, so that it can be usefully utilized as a composition for treating cartilage damage disease with excellent therapeutic effects without causing side effects.
Absstract of: WO2024211865A2
The current disclosure relates to lipid-based compositions and methods of administering therapeutic agents relating thereto. In particular, the disclosure relates to lipid-like substituted aryl and/or heteroaryl compounds, substituted piperazines, and/or other aryl and/or heteroaryl lipid compounds as LNP delivery materials that may be incorporated into lipid-based compositions to increase efficiency of delivery of a therapeutic agent(s) to tissues of a subject.
Absstract of: AU2024250317A1
The present disclosure relates to an RNA delivery vehicle comprising lipid nanoparticles comprising the RNA therein, and a RNA-binding protein or peptide coated on the exterior surface of the lipid nanoparticle, and uses thereof.
Absstract of: WO2024207006A2
A method of prophylactically or therapeutically vaccinating a subject for cancer comprising administering to the subject an immune response-inducing effective amount of a composition comprising (a) an agonist of the stimulator of interferon (IFN) genes (STING) and (b) a tumor (or cancer) antigen or neoantigen, both (a) and (b) of which are adsorbed onto cationic phytoglycogen (PG) nanoparticles; a microneedle device (e.g., microneedle patch) comprising a plurality of microneedles on/in which are contained cationic PG nanoparticles onto which are adsorbed (i) a STING agonist and (ii) a tumor (or cancer) antigen or a neoantigen; a needle-free injector comprising cationic PG nanoparticles onto which are adsorbed (i) a STING agonist and (ii) a tumor (or cancer) antigen or neoantigen; and a kit comprising (a) a microneedle device or a needle-free injector and (b) a composition comprising cationic PG nanoparticles onto which are adsorbed (i) a STING agonist and (ii) a tumor (or cancer) antigen or neoantigen.
Absstract of: CN121013733A
Described herein are lipid nanoparticle (LNP) formulations for the delivery of active agents, including Archexin.
Absstract of: EP4691619A1
The present invention relates to a device useful for producing nanoparticles that include hydrophobic and hydrophilic substances. Specifically, the device according to the present invention is characterized by including: a plurality of inlet channels into which the hydrophobic and hydrophilic substances are respectively introduced; a mixing channel in which the substances are mixed to produce the nanoparticles; and an outlet channel through which the produced nanoparticles are discharged, wherein the mixing channel includes microposts capable of increasing the mixing efficiency of the substances. Therefore, the nanoparticles produced using the device according to the present invention exhibit excellent particle uniformity and can be effectively used as drugs or drug delivery carriers.
Absstract of: EP4691476A1
The present invention provides a method for producing nucleic acid-encapsulating lipid nanoparticles, including the following steps (a) and (b):step (a) of mixing an alcohol solution containing an ionic lipid having a tertiary amino group, a sterol, and a PEG lipid with a citrate buffer having pH 3 to 6.5 in which nucleic acid is dispersed to prepare a suspension of nucleic acid-encapsulating lipid nanoparticles; andstep (b) of exchanging a dispersion medium of the aforementioned suspension for a Tris buffer having pH 5.2 to 9.0 by concentrating the suspension of nucleic acid-encapsulating lipid nanoparticles by ultrafiltration and diluting same with the aforementioned Tris buffer.
Absstract of: CN121001708A
The invention relates to an oil-in-water nanoemulsion in a stable pressurized container. The nanovesicles contained in the nanoemulsion are particularly stable in terms of vesicle particle size and vesicle particle size uniformity after long-term storage at different temperatures.
Absstract of: WO2024209013A1
The present invention relates to the field of lipid nanoparticles (LNPs). In particular, the present invention relates to an LNP composition comprising a cationic or cationically ionisable lipid or lipid-like material, a helper lipid, a lipopolymer, and a monomycoloyl glycerol (MMG) analogue. The LNP composition is particularly useful as a vaccine composition.
Absstract of: WO2024201468A1
Methods, kits and material composition for use in correction of eye condition are disclosed. This includes a selected three-dimensional patterning on the surface of a cornea of a user. The pattern is selected to provide an optical effect in accordance with a predetermined vision impediment of the user. A dispersion, in the form of a liquid (aqueous solution) comprising nanoparticles, is applied onto said selected three- dimensional pattern such that the nanoparticles are dispersed in incision regions of the pattern. The nanoparticles comprise biocompatible protein based nanoparticles. The dispersion may be used as eye drops thereby allowing the nanoparticles to occupy the etching regions on the cornea, thereby functionalizing and maintaining the visual correction effect of eye condition by said pattern. The present disclosure further provides a method and a kit for ablating the corneal tissue in a selected pattern by using a visual spectrum illumination.
Absstract of: CN120916750A
The present invention relates to an oil-in-water nanoemulsion substantially free of propylene glycol. The nanovesicle formulations are particularly stable in shelf life at different storage temperatures.
Nº publicación: EP4687992A1 11/02/2026
Applicant:
OSE IMMUNOTHERAPEUTICS [FR]
OSE IMMUNOTHERAPEUTICS
Absstract of: AU2024254671A1
The invention relates to a method for producing a lipid-based nanoparticle comprising an antigen binding domain and one or several nucleic acid molecule(s) using a mixing device, to a lipid-based nanoparticle comprising an antigen-binding domain and one or several nucleic acid molecule(s) obtainable trough such method and to uses thereof.
BOPI
Electronic site
